Medexus Pharmaceuticals (TSE:MDP) Cut to “Hold” at Stifel Nicolaus

Stifel Nicolaus cut shares of Medexus Pharmaceuticals (TSE:MDP) from a buy rating to a hold rating in a report released on Friday morning,BayStreet.CA reports. They currently have C$3.45 target price on the stock, down from their previous target price of C$6.00.

A number of other research analysts have also issued reports on the company. Leede Financial upgraded Medexus Pharmaceuticals from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, January 22nd. Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. Ventum Financial boosted their price objective on Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the stock a “buy” rating in a research report on Thursday, January 30th. Ventum Cap Mkts raised shares of Medexus Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 17th. Finally, Raymond James upgraded shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price target for the company in a report on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating, one has assigned a buy rating and five have given a strong buy rating to the company. Based on data from MarketBeat.com, Medexus Pharmaceuticals presently has a consensus rating of “Strong Buy” and a consensus target price of C$5.49.

Medexus Pharmaceuticals Stock Up 5.2 %

Medexus Pharmaceuticals stock opened at C$3.21 on Friday. Medexus Pharmaceuticals has a 52-week low of C$1.47 and a 52-week high of C$5.56. The firm has a market cap of C$78.74 million, a PE ratio of 64.20 and a beta of 1.96. The company’s 50 day moving average is C$3.53 and its two-hundred day moving average is C$2.82.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.